Helene Sundt AS (investor - Corporate Investor)

Norway
See something wrong or missing? Let us know

Helene Sundt AS is part of the holding company Sundt, together with CGS Holding AS and the investment company Sundt AS.

Petter C.G. Sundt, a Norwegian ship owner and businessman, established Sundt AS in 1995 as a privately owned investment company and managed the company until his passing in 2007 when his children, Helene and Christian G. Sundt, inherited the company. They have carried on their father’s business strategy as well as a strong commitment to the Bergesen charitable foundation.

Average round investment:14.55M USD
Average number per year:1.0
Distribution: 2020 (1)2017 (1)
Portfolio companies: Norway Oncoinvent
Mostly invests in: Norway Norway (2) Biotech (2)

2 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Helene Sundt AS

Name Criteria
Sweden CGS Holding AS
70%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Norway
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Advent Life Sciences
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Agilent Technologies
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Alter Equity
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy AurorA Science
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Biospring Partners
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Essential Investments
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Jaquet Partners
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Longwall Ventures
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top